aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Kaleido Biosciences is a Massachusetts-based biotech firm focused on leveraging the potential of the microbiome organ to treat disease and improve human health. The company develops innovative healthcare solutions driven by advanced chemistry, aiming to address various medical conditions and enhance patient outcomes.
Kaleido Biosciences has made significant strides in microbiome research, contributing valuable insights and therapeutic approaches to the healthcare industry. Its impact is evident in the advancement of microbiome-based treatments, positioning the company as a leader in this specialized field.
Operating Status
Closed
Ownership Type(s)
Public
Main Product(s)
Therapeutics, Healthcare
Technology
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Kaleido Biosciences founded?
Kaleido Biosciences was founded in 2015.
Where is Kaleido Biosciences’s headquarters located?
Kaleido Biosciences’s headquarters is located in Lexington, MA, US.
When was Kaleido Biosciences’s last funding round?
Kaleido Biosciences’s most recent funding round was for $60.4M (USD) in February 2021.
How many employees does Kaleido Biosciences have?
Kaleido Biosciences has 76 employees as of Feb 6, 2024.
How much has Kaleido Biosciences raised to-date?
As of July 05, 2023, Kaleido Biosciences has raised a total of $230.9M (USD) since Feb 4, 2021.
Add Comparison
Total Raised to Date
$230.9M
USD
Last Update Feb 4, 2021
Last Deal Details
$60.4M
USD
Feb 4, 2021
Post Ipo Equity
Total Employees Over Time
76
As of Feb 2024
Kaleido Biosciences Address
65 Hayden Avenue
Lexington,
Massachusetts
02421
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts